Spodick sign is a highly specific, albeit frequently under-recognized, electrocardiographic (ECG) finding classically observed during Stage I acute pericarditis 1,2. First formally characterized by Dr. David H. Spodick in 1974, the sign manifests as a distinct downward sloping of the TP segment (the baseline interval between the end of the T wave and the onset of the subsequent P wave) 1,2. Best visualized in lead II and the lateral precordial leads (V4 through V6), Spodick sign serves as a crucial bedside discriminator when differentiating acute inflammatory pericardial syndromes from acute coronary syndromes, particularly ST-elevation myocardial infarctions (STEMI) 3. Recognizing this sign prevents misdiagnosis and averts inappropriate utilization of invasive coronary angiography or thrombolytic therapy.

Etiology & Risk Factors

  • Viral Infections: The predominant worldwide etiology of acute pericarditis, including Coxsackieviruses A and B, echoviruses, adenoviruses, influenza, Epstein-Barr virus, cytomegalovirus, and SARS-CoV-2.
  • Idiopathic Pericarditis: Encompasses up to 80 to 90% of cases in developed nations, presumed to be post-viral or immunologically mediated where a specific pathogen is never isolated.
  • Autoimmune and Inflammatory Disorders: Systemic lupus erythematosus (SLE), rheumatoid arthritis, Sjögren syndrome, systemic sclerosis, mixed connective tissue disease, and familial Mediterranean fever.
  • Autoinflammatory Syndromes: Pericarditis associated with interleukin-1-driven pathways, including adult-onset Still disease and recurrent idiopathic pericarditis.
  • Post-Cardiac Injury Syndromes: Dressler syndrome following acute myocardial infarction, post-pericardiotomy syndrome following cardiac surgery, and complications from percutaneous coronary interventions or pacemaker implantations.
  • Systemic and Metabolic Diseases: Uremic pericarditis secondary to end-stage renal disease, severe hypothyroidism (myxedema), malignant neoplasms (direct extension or metastasis from lung, breast, lymphoma, or leukemia), and amyloidosis.
  • Pharmacological and Toxic Triggers: Drug-induced lupus or hypersensitivity reactions linked to procainamide, hydralazine, phenytoin, isoniazid, penicillin, and minoxidil.
  • Demographic Predilections: Higher clinical incidence among young adult males aged 20 to 50 years, though metabolic, malignant, and uremic etiologies present predominantly in older populations 1.

Pathophysiology

The pathophysiological foundation of Spodick sign is rooted in the diffuse subepicardial inflammation that characterizes Stage I acute pericarditis 2. When noxious agents or immune complexes provoke the visceral and parietal layers of the pericardium, the underlying superficial myocardial layers undergo contiguous inflammation (focal myopericardial irritation) 2,3. This transmural inflammatory response alters cellular resting membrane potentials and disrupts normal epicardial repolarization currents. Consequently, early repolarization changes and PR-segment alterations manifest across the surface ECG 3. The TP segment, traditionally utilized as the baseline reference for determining isoelectric stability, becomes depressed and slopes downward toward the subsequent P wave as a result of ongoing atrial repolarization abnormalities and localized epicardial current vectors 2. When evaluated across lateral leads where repolarization forces are prominent, this baseline downsloping creates the characteristic Spodick morphology 3.

Spodick sign — Pathophysiological Cascade & Clinical Flowchart 1 Pericardial Inflammation Viral or idiopathic pericardial irritation disrupts subepicardial repolarization currents. 2 Baseline Baseline Shift Early atrial repolarization changes manifest as downward sloping of the TP segment between heartbeats. 3 Epicardial Electrophysiology Widespread transmural inflammatory involvement alters baseline voltage referencing across lateral precordial leads. 4 Diagnostic Sign Identification Observation of downsloping TP segment of at least 1 mm in lead II and lateral precordial leads (V4-V6). 5 Prevention of Recurrence Targeted anti-inflammatory therapy with NSAIDs and colchicine prevents chronic inflammation and constrictive sequelae.

Clinical Presentation & Classic Clinical Signs

  • History & Cardinal Symptoms: Patients classically present with sudden-onset, sharp, pleuritic retrosternal chest pain that frequently radiates to the trapezius ridge (the most specific anatomical pointer reflecting diaphragmatic irritation of the phrenic nerve). Pain characteristically intensifies with deep inspiration, coughing, swallowing, and recumbency, while providing consistent relief upon sitting upright and leaning forward. Low-grade, remittent fevers, malaise, and nonproductive cough often precede or accompany the pain in viral etiologies.
  • Physical Examination & Named Clinical Signs: The hallmark auscultatory finding is the pericardial friction rub—a high-pitched, superficial, scratchy, or squeaky sound often described as resembling leather rubbing against leather. It characteristically exhibits three components per cardiac cycle (atrial systole, ventricular systole, and early ventricular diastolic filling), though it may be transient, shifting, or audible in only a fraction of patients. Clinicians must meticulously auscultate with the diaphragm of the stethoscope firmly pressed against the left sternal border while the patient is leaning forward at end-expiration. In severe inflammatory states or impending tamponade, examination may reveal tachycardia, diminished heart sounds, and pulsus paradoxus (an inspiratory drop in systolic blood pressure exceeding 10 mmHg).

Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Diagnostic Modality / Test Expected Clinical & Radiological / Laboratory Finding
Gold-Standard InvestigationTransthoracic Echocardiography (TTE) demonstrating a new or worsening pericardial effusion, normal or hyperdynamic left ventricular systolic function, and absence of regional wall motion abnormalities.
Laboratory PanelElevated acute-phase reactants including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Troponin I or T may be mildly elevated in myopericarditis due to superficial myocardial involvement. Leukocytosis and baseline renal panels (BUN/creatinine) evaluate uremic origins.
Imaging / Radiology (X-ray, US, CT, MRI)Chest radiography is frequently normal or demonstrates an enlarged "water-bottle" cardiac silhouette if a substantial effusion (>250 mL) is present. Cardiac Magnetic Resonance (CMR) imaging demonstrates late gadolinium enhancement (LGE) of the pericardium, confirming active inflammation and edema.
ECG / Histopathology / Procedural12-lead ECG displaying Stage I changes: diffuse concave upward ST-segment elevations across multiple leads (excluding aVR and V1), PR-segment depression, reciprocal PR elevation and ST depression in leads aVR and V1, and the presence of Spodick sign (TP-segment downsloping of at least 1 mm in lead II and lateral precordial leads). Pericardial biopsy is reserved for refractory or suspected malignant/granulomatous etiologies.

Staging, Classification & Clinical Scoring Systems

Criterion / Stage / Score Component Clinical Threshold, Points & Management Implication
Stage I (Acute Pericarditis)First week of presentation: Widespread concave ST elevations, PR segment depression, and Spodick sign (TP downsloping). Managed with high-dose anti-inflammatory therapy.
Stage II (Subacute Resolution)Occurs within week 2: Normalization of ST and PR segments, with flattening of T waves. Tapering of anti-inflammatory medications can be initiated if CRP normalizes.
Stage III (T-Wave Inversion)Occurs across weeks 2 to 3: Widespread asymmetric T-wave inversions develop as ST segments become isoelectric. Patient must remain physically restricted.
Stage IV (Complete Resolution)Occurs after several weeks to months: Normalization of T waves and baseline ECG patterns. Indicates successful resolution of active myocardial-pericardial inflammation.
European Society of Cardiology (ESC) Diagnostic CriteriaRequires at least 2 of the following 4 criteria for definitive diagnosis: (1) Pericarditic chest pain, (2) Pericardial friction rub, (3) New widespread ST elevation or PR depression on ECG, (4) New or worsening pericardial effusion on echocardiography.

Differential Diagnosis

Differential Condition Distinguishing Clinical, Biochemical & Imaging Features
ST-Elevation Myocardial Infarction (STEMI)Presents with localized chest pressure rather than sharp pleuritic pain. ECG demonstrates convex upward ("frowny") ST elevations, reciprocal ST depressions in anatomically opposing leads, localizing Q waves, absence of PR depression, and horizontal or upward-sloping TP segments (Spodick sign absent or rare). Coronary angiography reveals obstructive coronary thrombus.
Early Repolarization Variant (Normal Variant)Typically benign finding in young, healthy athletes. Demonstrates J-point notching or slurring, stable serial ECG tracings without dynamic evolution through stages, upright T waves with a high T/ST voltage ratio (>0.25 in lead V6), and absence of PR-segment depression or Spodick sign.
Pulmonary EmbolismPresents with acute dyspnea, pleuritic pain, and tachycardia. ECG may show S1Q3T3 pattern, incomplete or complete right bundle branch block, and lead V1-V3 T-wave inversions. Computed tomography pulmonary angiography (CTPA) confirms filling defects in the pulmonary arterial tree.
Aortic DissectionPresents with abrupt, severe tearing or ripping chest or back pain frequently radiating between the scapulae, often accompanied by pulse deficits or focal neurological deficits. Spodick sign and pericarditic features are absent. Diagnosed definitively via contrast-enhanced CT aortography or transesophageal echocardiography.

Management & Treatment Protocol

  • Initial Stabilization & Resuscitation: Assess hemodynamic stability immediately. Monitor continuously via telemetry and pulse oximetry. Perform bedside focused cardiac ultrasound (POCUS) to rule out cardiac tamponade if hypotension, jugular venous distension, and muffled heart sounds (Beck triad) are present. If tamponade is identified, perform urgent pericardiocentesis under echocardiographic or fluoroscopic guidance.
  • First-Line Medical / Pharmacological Therapy (with exact adult dosing):
    • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): The cornerstone of inflammation suppression. Ibuprofen administered at 600 mg to 800 mg orally every 8 hours (maximum 2,400 mg daily), or Aspirin administered at 650 mg to 1,000 mg orally every 8 hours. Treatment is maintained at full anti-inflammatory doses until symptoms resolve and serum CRP normalizes, followed by a gradual taper over 2 to 4 weeks. Gastroprotection with a proton pump inhibitor (e.g., Pantoprazole 40 mg orally daily) should be co-prescribed.
    • Colchicine: Mandatory adjunct therapy to prevent recurrence and accelerate remission. Administered at 0.5 mg orally twice daily for patients weighing >70 kg, or 0.5 mg orally once daily for patients weighing ≤70 kg or with chronic kidney disease (eGFR 30–50 mL/min). Maintained for a total duration of 3 months for a first episode (and up to 6 months for recurrences), followed by cessation without a taper.
  • Second-Line and Adjunctive Agents:
    • Corticosteroids: Reserved for patients with specific indications (contraindications to NSAIDs/colchicine, systemic autoimmune disease, or uremic pericarditis) or refractory cases. Dosed as Prednisone at 0.2 mg to 0.5 mg/kg/day orally, tapered extremely slowly over weeks to months once CRP normalizes to prevent rebound recurrence.
    • Interleukin-1 Inhibitors: Rilonacept or anakinra for patients with recurrent, corticosteroid-dependent pericarditis refractory to conventional therapy.
  • Activity Restriction: Strict avoidance of competitive sports and strenuous physical exertion until complete symptom resolution and normalization of CRP and ECG findings, typically for a minimum of 3 months, to minimize the risk of recurrence or progression to chronic constrictive physiology.

Complications & Prognosis

  • Pericardial Effusion and Cardiac Tamponade: Up to 60% of acute pericarditis patients develop a demonstrable pericardial effusion 4. Rapid accumulation of fluid restricts diastolic ventricular filling, precipitating life-threatening obstructive shock (cardiac tamponade) requiring emergent decompression.
  • Recurrent Pericarditis: Occurs in 15% to 30% of patients following an initial episode, rising to 50% after subsequent recurrences if colchicine is omitted or prematurely discontinued 1.
  • Constrictive Pericarditis: A long-term, irreversible complication where chronic fibrous scarring and calcification of the pericardial sac encase the heart, causing fixed diastolic filling failure, elevated venous pressures, hepatomegaly, ascites, and peripheral edema. Idiopathic and viral cases carry a low risk (<1%), whereas purulent and tuberculous etiologies carry a significantly higher risk.
  • Myopericarditis: Concomitant myocardial involvement characterized by biomarker elevation (troponin) and left ventricular dysfunction, requiring close monitoring for malignant arrhythmias and heart failure 4.
  • Prognosis: Idiopathic and viral acute pericarditis carry an excellent overall long-term prognosis when managed appropriately with combined NSAID and colchicine protocols, with low overall mortality in the absence of underlying systemic disease or malignant etiologies 1,4.